STAMPEDE
Restarting Recruitment Checklist – Covid-19

Site Name:	**Site No:**

Please refer to the STAMPEDE specific guidance on trial conduct during the Covid-19 pandemic located here http://www.stampedetrial.org/centres/information-on-covid-19/ and complete the checklist below, in discussion with your colleagues, to confirm that you are able to adhere to all requirements.

	Q1-11 must be answered YES to be able to open to recruitment	**Yes**	**No**
1	Can you confirm that key staff members (e.g. PI, RNs) are in post and have capacity to undertake further recruitment to the trial in addition to follow-up of previously recruited participants	☐	☐
2	Can you fully assess eligibility at randomisation	☐	☐
3	Can you conduct the informed consent process, as per the consent guidance found here: http://www.stampedetrial.org/centres/recruitment-and-covid-19/	☐	☐
4	Can you receive and dispense drug to participants (either in person or via post/courier)	☐	☐
5	Can you adhere to the protocol follow-up schedule and conduct all mandatory assessments	☐	☐
6	Can you continue to submit CRFs to MRC CTU (preferably via fax or Galaxkey)	☐	☐
7	Can you confirm that the risk of exposure of patients and staff to Covid-19 has been mitigated	☐	☐
8	Can you confirm that intention to restart recruitment has been discussed and approved by your local R&D department	☐	☐
9	Can you confirm that intention to restart recruitment has been discussed and agreed by the Principal Investigator	☐	☐
10	Can you confirm you have read the STAMPEDE Covid-19 guidance found here: http://www.stampedetrial.org/centres/information-on-covid-19/	☐	☐
11	Does your site want to open to recruitment	☐	☐
12	Can you accommodate on-site monitoring	☐	☐

Principal Investigator Name *(please print)*	
Principal Investigator Signature	
Date Signed	

Please fax to STAMPEDE trial on **0207 670 4818 or** email to **mrcctu.stampede@ucl.ac.uk**

For completion by MRC CTU:

Name of reviewer		
Approval to restart recruitment	☐ Yes	☐ No
If No, please provide reason for this		
Date of review		